Elevation Oncology Inc [ELEV] stock is trading at $0.49, up 5.02%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ELEV shares have gain 1.60% over the last week, with a monthly amount drifted -21.71%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Piper Sandler started tracking the stock with Overweight rating on May 31, 2024, and set its price target to $10. On May 14, 2024, Stephens initiated with a Overweight rating and assigned a price target of $8 on the stock. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $7 on March 01, 2024. SVB Securities upgraded its rating to a Outperform and raised its price target to $8 on May 30, 2023. H.C. Wainwright started tracking with a Buy rating for this stock on December 23, 2021, and assigned it a price target of $12.
Elevation Oncology Inc [ELEV] stock has fluctuated between $0.41 and $5.83 over the past year. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Elevation Oncology Inc [NASDAQ: ELEV] shares were valued at $0.49 at the most recent close of the market. An investor can expect a potential return of 1736.73% based on the average ELEV price forecast.
Analyzing the ELEV fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.62 and Total Capital is -0.49. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.52.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.4651 points at the first support level, and at 0.4361 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.5193, and for the 2nd resistance point, it is at 0.5445.
Ratios To Look Out For
For context, Elevation Oncology Inc’s Current Ratio is 21.21. As well, the Quick Ratio is 21.21, while the Cash Ratio is 11.07.
